Achieve Life Sciences, INC.: management transactions · United States · SEC (Form 4)

About Achieve Life Sciences, INC.

Achieve Life Sciences, Inc. (ticker: ACHV) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. The company operates with a dual footprint in Bothell/Seattle, Washington, and Vancouver, British Columbia, but its corporate identity and capital-market access are firmly anchored in the United States. Achieve is a specialty pharmaceutical company focused on a single therapeutic theme: nicotine dependence. Its lead asset is cytisinicline, an investigational therapy intended for smoking cessation and, potentially, vaping cessation as well. ([sec.gov](https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/achv-20260415.htm?utm_source=openai)) Historically, Achieve was built around clinical research aimed at addressing nicotine addiction, and its current strategy remains highly concentrated rather than diversified. The company describes itself as a late-stage specialty pharmaceutical business, which is important for investors because it signals a development model driven by clinical milestones, regulatory events, and eventual commercialization rather than a broad portfolio of marketed products. In practical terms, ACHV is essentially a single-asset story, with shareholder value heavily dependent on cytisinicline’s clinical, regulatory, and launch execution. ([ir.achievelifesciences.com](https://ir.achievelifesciences.com/news-events/press-releases/detail/257/achieve-life-sciences-announces-up-to-354-million-private-placement?utm_source=openai)) From a competitive standpoint, Achieve targets a large public-health market that remains underserved: tobacco cessation and the broader treatment of nicotine dependence. The company positions cytisinicline as a potential new option in a therapeutic area that has seen limited innovation for many years. Its core activities therefore include drug development, manufacturing readiness, regulatory preparation, and commercialization planning. In April 2026, Achieve announced completion of the technology transfer for manufacturing to U.S.-based Adare Pharma Solutions, an operational step that strengthens its readiness for a possible launch in the United States. ([ir.achievelifesciences.com](https://ir.achievelifesciences.com/news-events/press-releases/detail/256/achieve-life-sciences-announces-operational-progress-including-completion-of-technology-transfer-to-adare-pharma-solutions?utm_source=openai)) Geographically, the company’s operating base is primarily North American, with U.S. headquarters and a Vancouver presence, while management has described the commercialization opportunity as global. For investors, ACHV represents a classic small-cap biotech catalyst profile: the upside case depends on regulatory progress rather than on current product revenue diversification. A key near-term milestone is the FDA PDUFA target action date of June 20, 2026 for cytisinicline in smoking cessation. Management has also highlighted the potentially larger vaping-cessation opportunity, and the company recently announced a private placement of up to $354 million, the appointment of Andrew D. Goldberg as CEO, and additional board and commercial leadership additions in May 2026. ([ir.achievelifesciences.com](https://ir.achievelifesciences.com/news-events/press-releases/detail/247/achieve-life-sciences-reports-third-quarter-2025-financial-results-provides-updates-on-cytisinicline-program?utm_source=openai))